Nicolas Demogeot, MD

Institut de Cancerologie de Lorraine
Vandoeuvre Les Nancy, Meurthe-et-Mosel

Disclosures:

• Employment: none
• Compensation: Astellas: Advisory Board, Advisory Board Type, Advisory Board Proprietary, Honoraria-End Date: 22/03/23
• Ownership: none
• Leadership: none

Presentation(s):

• LBA06 - Short-Term Androgen Deprivation Therapy and High-Dose Radiotherapy in Intermediate- and High-Risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase III Trial

  Sunday, September 29, 2024
  2:10 PM – 2:20 PM ET